Biocon Share Price
Free Demat with Zero AMC*
+ Free 1st Year AMC
Summary
The stock has recorded a trading volume of 34,45,639 shares,. Its Average Traded Price (ATP) is ₹363.71, while the Last Traded Quantity at the Last Traded Price (LTQ@LTP) is 33 @ ₹361.95.
Biocon has an upper circuit limit of ₹395.30 and a lower circuit limit of ₹323.50. The total value traded stands at ₹125.32 CR, and the delivery percentage for the day is 54.52%.
The stock is currently traded with a market lot size of 1. Biocon also offers a dividend yield of 0.14%.
Biocon Share Price Chart
Biocon Share Key Metrics
Volume
34.46 L
Market Cap
58986.78 CR
LTQ@LTP
33@361.95
ATP
363.71
Var Margin
14.64 %
Circuit Range
323.5-395.3
Delivery %
54.52 %
Value
125.32 CR
ASM/GSM
No
Market Lot
1
Biocon Resistance and Support
Pivot 360.32
Resistance
First Resistance
362.24
Second Resistance
365.07
Third Resistance
366.99
Support
First Support
357.49
Second Support
355.57
Third Support
352.74
Biocon Futures & Options
361.95
2.55 (0.71%)
Biocon Option Chain
View Price, OI, Greeks & More...
23NOV26
0.00
NaN (%)
29DEC26
0.00
NaN (%)
25JAN27
0.00
NaN (%)
BIOCON|23NOV26 CE 360.00
5.00
0.45 (9.89%)
BIOCON|23NOV26 PE 365.00
5.25
-2.05 (-28.08%)
Biocon Shareholding Pattern
View More- 2016-17
- 2018-19
- 2019-20
- 2020-21
- 2021-22
- 2022-23
- 2023-24
- 2024-25
- 2025-26
- 2026-27
Total Promoters
Biocon Corporate Actions
| Date | Agenda |
|---|---|
| 2026-11-04 | Quarterly Results |
| 2026-08-05 | Quarterly Results |
| 2026-05-07 | Audited Results & Final Dividend |
| 2026-02-12 | Quarterly Results |
| 2025-11-11 | Quarterly Results |
| 2025-10-01 | Redemption (Part) of NCD |
| 2025-08-07 | Quarterly Results |
| 2025-05-08 | Audited Results & Final Dividend |
| 2025-04-23 | Others |
| 2025-04-04 | To consider Fund Raising |
| 2025-01-30 | Quarterly Results & Others |
| 2025-01-27 | Others |
| 2024-10-30 | Quarterly Results |
| Ex Date | Record Date | |
|---|---|---|
| 2026-07-03 | 2026-07-03 | View More |
Biocon News
Biocon Ltd - 532523 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Biocon has received European Commission marketing authorization for Pebrilzo, its biosimilar pertuzumab for treating HER2-positive breast cancer. It is the first biosimilar approved under EMA's new tailored clinical approach, strengthening Biocon's oncology portfolio.
Nov 18 2026 08:33:41
Biocon Ltd - 532523 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Biocon received US FDA approval for Pebrilzo, a biosimilar to Perjeta, used for treating HER2-positive breast cancer. This marks the company's fifth oncology biosimilar approved in the US, with an earliest expected launch in Q3 2028 following a global settlement with Genentech.
Nov 16 2026 08:36:08
Biocon Ltd - 532523 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Biocon reported a 52% YoY decline in Q2 FY27 net profit to Rs.41 crore, with total income remaining flat at Rs.4,423 crore. The company also secured a 10-year biosimilar Pertuzumab partnership in Brazil valued at approximately $400 million.
Nov 04 2026 13:23:40
Biocon Ltd - 532523 - Board Meeting Outcome for Outcome Of Board Meeting
Biocon Limited reported Q2 FY27 cons. revenue of ₹4,389 crores (up 2% YoY) and net profit of ₹57 crores (down 57% YoY). The board appointed Mukesh Rathi as the new Chief Technology Officer, effective January 1, 2027, following the resignation of Dr. Mandar Shrikant Ghatnekar. Rathi brings over 27 years of experience from Hinduja Group and Dr. Reddy’s Laboratories.
Nov 04 2026 13:21:39
Biocon Ltd - 532523 - Board Meeting Intimation for To Approve And Take On Record The Un-Audited Standalone And Consolidated Financial Results Of The Company For The Quarter And Half Year Ended On September 30, 2026
Biocon's board will meet on 4 November 2026 for the financial results of Q2 FY27. An earnings conference call for analysts and investors will follow on the same day.
Oct 26 2026 20:31:26
Biocon Ltd - 532523 - Company Statement
Biocon signed a license agreement with Janssen Sciences Ireland to commercialize Yesintek (biosimilar to Stelara) in nine global markets including Australia, Brazil, and China. This grants immediate market entry rights for the autoimmune treatment.
Oct 26 2026 08:27:48
Biocon Management
| Name | Position |
|---|---|
| Kiran Mazumdar-Shaw | Chairperson |
| Ravi Rasendra Mazumdar | Non Independent & Non Executive Director |
Biocon Similar Stocks
Lupin Ltd.
1971.90
21.90 (1.12%)
Glenmark Pharmaceuticals Ltd.
2646.10
30.30 (1.16%)
Aster DM Quality Care Ltd.
731.00
-6.95 (0.94%)
Alkem Laboratories Ltd.
5222.50
47.50 (0.92%)
Fortis Healthcare Ltd.
793.55
-13.25 (1.64%)
Gland Pharma Ltd.
3230.50
-17.90 (0.55%)
Abbott India Ltd.
25470.00
-345.00 (1.34%)
Anthem Biosciences Ltd.
914.35
-9.90 (1.07%)
Ipca Laboratories Ltd.
1854.10
19.70 (1.07%)
Glaxosmithkline Pharmaceuticals Ltd.
2638.20
-49.40 (1.84%)
Biocon FAQs
Open Your Free
Demat Account Now!
AMC for First Year
Auto Square Off Charges
+ Free 1st Year AMC
13 Lakh+ Clients
Expert-Backed
Premium Tools

Open Your Free
Demat Account Now!
AMC For First Year
Account Opening Fee
+ Free 1st Year AMC
13 Lakh+ Clients
Expert-Backed
Premium Tools
Invest in BIOCON
Account Opening Fee AMC for 1st Year Auto Square Off Charges Call & Trade
+ Free 1st Year AMC